Khan Najat
- SEC CIK
- 0002020969
In the past year, 4 open-market sale filings worth $806.7K and no purchases.
Current role at each company
- RXRX Recursion Pharmaceuticals, Inc.CEO and Presidentas of Sep 10, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $806.7K
- 4 filings
- Net
- −$806.7K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Khan Najat as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 (view filing)5:55 PM ET | Sep 8 | 2 days | Khan NajatCEO and President | SSaleClass A Common Stock | −22.4K | $3.52 | −$78.8K | −1.1%2.07M after | 10b5-1 |
| Jun 5, 2026 (view filing) | Jun 5 | Same day | Khan NajatCEO and President | SSaleClass A Common Stock | −23.6K | $3.58 | −$84.4K | −1.1%2.18M after | 10b5-1 |
| Mar 11, 2026 (view filing) | Mar 9 | 2 days | Khan NajatCEO and President | SSaleClass A Common Stock | −28.3K | $3.35 | −$94.8K | −1.2%2.26M after | 10b5-1 |
| Dec 29, 2025 (view filing) | Dec 22 | 7 days | Khan NajatChief R&D Commercial Officer | SSaleClass A Common Stock | −124.4K | $4.41 | −$548.6K | −16.9%611.1K after | 10b5-1 |
| Aug 19, 2025 (view filing) | Aug 18 | 1 day | Khan NajatChief R&D Commercial Officer | SSaleClass A Common Stock | −36.6K | $5.52 | −$202.0K | −5.2%668.2K after |